Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance

Nishi Prabdial-Sing1,2, Lillian Makhathini1, Sheilagh Brigitte Smit1, Morubula Jack Manamela1, Nkengafac Villyen Motaze1,3, Cheryl Cohen4,5, Melinda Shelley Suchard1,6*

1 Centre for Vaccines and Immunology, National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa, 2 Department of Virology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 3 Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 4 Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa, 5 School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, 6 Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

* melindas@nicd.ac.za

Abstract

Introduction and methods
Hepatitis B is a vaccine preventable disease and is notifiable in South Africa. Hepatitis B vaccination was incorporated into the Expanded Programme on Immunisation in South Africa in 1995. We used a convenience sample from community-based febrile rash surveillance in 2013 to estimate hepatitis B sero-prevalence. Of samples serologically negative for acute measles infection, 450 samples spanning nine provinces of South Africa were tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc).

Results
Two children (2/450; 0.4%) tested positive for HBsAg. Three hundred and three children (67.3%) had evidence of vaccine induced immunity. Vaccine induced immunity was present in 80.2% of 1–5 year olds, but only 60.3% of 10–14 year olds. Natural immunity, indicating exposure to circulating hepatitis B, was present in 13/450 (2.9%) children.

Conclusion
Chronic hepatitis B in South African has decreased in prevalence from highly endemic levels prior to vaccine introduction to approximately 0.4% in this sample, demonstrating impact of a successful vaccination programme 18 years after introduction. Decreased vaccine-induced immunity with increasing age may reflect waning antibody titres over time.
Introduction

Hepatitis B is a vaccine preventable disease and is notifiable in South Africa. There is no active national surveillance for hepatitis B. We estimated hepatitis B seroprevalence in South African children using residual sera from febrile rash surveillance.

Prior to vaccine introduction, South Africa was considered a country of high hepatitis B endemicity, defined as ≥8% prevalence for hepatitis B surface antigen (HBsAg) in the general population[1]. Rates of 5–16% for hepatitis B surface antigen were seen in rural black men, with lower rates in females, urban populations and other ethnic groups [2–5]. In the late 1980s in KwaZulu-Natal province, rates of 18.5% in rural and 10% in urban black children were reported, with rates of 2.5% in urban children under 6 years [6], while rates of 1% were reported in urban children 1–19 years of age in Soweto, Gauteng province [7]. Areas of the Eastern Cape in the 1990s had prevalence rates of 10% in children less than 6 years old [8]. Paediatric hepatitis B in South Africa in the pre-vaccine era was reported to be mostly due to horizontal transmission in childhood rather than vertical transmission from mother to child. Modes of horizontal transmission are not well defined but may result from exposure amongst children to infectious saliva or open sores amongst other postulated mechanisms [3, 6, 9–12].

Hepatitis B vaccination was incorporated into the routine Expanded Programme on Immunisation in South Africa in 1995, administered at 6, 10 and 14 weeks of age. An 18-month booster dose was later added in 2015, as part of a hexavalent preparation [13]. The World Health Organisation and United Nations International Children’s Emergency Fund (UNICEF) estimates of third dose hepatitis B vaccine coverage range from 66–85% from 2006 to 2017 [14]. A birth dose was not part of the South African immunisation schedule during this period. Since universal hepatitis B vaccine introduction into infant schedules, prevalence of chronic hepatitis B infection, measured by presence of hepatitis B surface antigen has decreased globally [15]. High HIV prevalence rates in South Africa may, however, influence rates of vertical transmission to infants or chronic carriage amongst children[16, 17].

In 2012, HIV prevalence in South Africa was estimated at 12.2% overall, with prevalence of 2.4% in children 2–14 years [18]. In studies published since 2000, HBsAg prevalence in South African adults living with HIV has been reported as 0.4–9.4% in HIV clinics [19–28] and up to 22.9% using hospital-based residual sera [29–31]. In antenatal clinics, rates of HBsAg in pregnant women ranged from 0.4–5.8% in HIV-uninfected women and 2.1–7.4% in HIV-infected women [32–35]. Regarding influence of HIV on hepatitis B vertical transmission from mother to child, Chotun et al found 0.3% of infants born to HIV-infected women positive for HBsAg, dropping to 0.2% on follow up [16]. Hoffman et al found 0.5% of infants born to HIV infected mothers positive for HBsAg [17]. Regarding hepatitis B seroprevalence in children, Jooste et al screened South African HIV-infected children and adolescents and found 0.8% positive for HBsAg [36]. In outpatient clinics, Simani et al found HBsAg prevalence of 0.4% in children under two years old (with higher prevalence of 2.7% in HIV-infected children) [37].

Community-based rash surveillance is used as a detection system for possible measles infection. Serum samples of children who have rash and fever together with cough, coryza or conjunctivitis are sent to the National Institute for Communicable Disease for measles serology. Approximately 7000 samples are tested annually, of which usually less than 50 are positive for measles IgM. The remaining samples are from children with acute rash illness other than measles. Rash in children has many aetiologies including viral (measles, rubella, ECHO, coxsackie, parvovirus B19, herpesvirus 6 and others), bacterial and rickettsial infections and other non-infectious causes. Rash therefore may affect any sector of the population including multiple ethnic, socioeconomic and demographic groups.
In this study, hepatitis B infection, exposure and protection was measured in children less than 15 years of age. Residual surveillance samples were used as a proxy for children in the general community.

**Methods**

**Sample selection**

Of 7107 rash samples collected in 2013, 450 samples were sequentially selected from children less than 15 years of age that tested negative for measles and rubella IgM. Samples with insufficient serum volume (<600μl) were excluded. Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc) were tested. HBsAg positive samples were further tested for e antigen (HBeAg), antibodies to e antigen (anti-HBe), viral load and genotyping.

**Laboratory tests**

HBsAg and anti-HBc were run on the Architect instrument (Abbott, Germany) and values equal to or greater than 1.00 Sample/Cutoff (S/CO) were considered positive. Anti-HBs titres (Architect, Abbott, Germany) were reported as milli-international units per ml (mIU/ml) according to WHO international reference standard (Hollinger and Dreesman, 1986). Samples equal to or greater than 10mIU/ml were considered positive for anti-HBs. Samples positive for HBsAg were tested for HBeAg and anti-HBe (Architect, Abbot, Germany) with cutoff at 1.00 S/CO.

Hepatitis B viral load was performed on HBsAg positive samples using the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0, quantitative assay (Roche Molecular Systems, New Jersey, USA). Sequencing was performed on the polymerase region (nucleotides 2624–1240), overlapping the complete S region (nucleotides 2848–2835) using BigDye Terminator v3.0 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) on the ABI 3130XL Genetic Analyzer (Applied Biosystems) [38]. Neighbour-joining phylogenetic analysis with a bootstrap of 1000 replicates was conducted using Molecular Evolutionary Genetics Analysis (MEGA 5)[39].

**Data analysis**

Results are reported as indicative of chronic infection (HBsAg positive), vaccine induced immunity (HBsAg negative, anti-HBs positive,anti-HBc negative) or natural exposure (HBsAg negative, anti-HBc positive).

**Sample size**

Sample size calculation was conducted using Open-Epi software. Based on an anticipated 2% prevalence of HBsAg positive samples, with a 99% confidence level, confidence limits of +/- 2% and a design effect of 1, a minimum sample size of 350 samples was needed. The study was not powered to estimate hepatitis B prevalence stratified by age group or by province.

**Ethics**

This study was approved by the University of Witwatersrand Human Research Ethics committee (clearance certificate M140857). Subjects were not required to give informed consent as samples had been collected during routine febrile rash surveillance and were anonymized for this study.
Results
Of 450 samples selected, 47% were females and 53% were males, with a median age of 5 years. Ages of included children were 11 aged 0–11 months, 217 aged 1–5 years, 174 aged 6–10 years and 48 aged 11–14 years (2.4%, 48%, 38.7% and 10.7% respectively). Provincial distribution of samples included Mpumalanga 14% (n = 65) Eastern Cape 13% (n = 59), North West Province 13% (n = 58), Northern Cape 12% (n = 55), KwaZulu Natal 11% (n = 51), Free State 10% (n = 43), Limpopo 10% (n = 47), Gauteng 9% (n = 42) and Western Cape 7% (n = 30).

HBsAg was positive in two children, 0.4% (2/450) of the sample, a 2 year-old from Ehlanzeni in Mpumalanga province (HBeAg positive, viral load 4.6log<sub>10</sub> copies/ml) and a 12-year-old from Ethekwini Metro in KwaZulu-Natal (HBeAg negative, anti-HBe positive, viral load 2.6log<sub>10</sub> copies/ml). Both children were positive for anti-HBc and both samples were genotype A1.

Vaccine induced immunity (individuals positive for anti-HBs with negative anti-HBc [40]) was high in children under 1 year (81.8%) and 1–5 years (80.2%) but lower in older age groups (60.3% in 6–10 year olds and 31.3% in 11–15 year olds (Table 1). Overall, 2.9% of children (13/450) had evidence of natural exposure (anti-HBc) to hepatitis B, implying they had been exposed to circulating HBV at some time. Of the 450 samples tested, 132 (29.3%) had no serological markers positive, indicative of either no exposure to HBV, no exposure to hepatitis B vaccine, or perhaps prior vaccine induced immunity which may have waned with time.

Discussion
Our finding of 0.4% prevalence of hepatitis B infection in children under 15 years of age adds an estimate of burden of infection in the post vaccine era. While other studies have focused on targeted clinics (antenatal, HIV, immunisation, outpatient clinics) or used hospital-based residual sera, we have studied a community-based population. We found two cases positive for HBsAg, which may reflect either horizontally or vertically acquired infections.

Vaccine induced immunity was highest in infants and young children, decreasing in older age groups.

Age dependent decreases in rates of vaccine induced immunity could imply absence of vaccination, biological non-response to vaccine or waning of immunity. Reduction in immunity as age increases has been previously reported. [41–45]. Protection against infection may endure despite waning of anti-HBs titres, as immunologic memory produces anamnestic responses to boosters [45, 46]. Anti-HBs prevalence is therefore not a reliable indicator of community vaccination coverage or immunity to hepatitis B infection and should be interpreted with caution.

HIV infection was not tested in our samples, due to ethical sensitivities. We therefore cannot analyse whether carriage rates of hepatitis B in children differ in those who are HIV infected or exposed from those who are HIV uninfected. Occult hepatitis B infection was not investigated. Occult hepatitis B, usually considered as detectable hepatitis B deoxyribonucleic acid (DNA) but undetectable HBsAg, has previously been reported in both HIV negative and HIV positive adults [20, 29, 30, 34, 35, 47] and HIV exposed infants [16, 17, 48] in South Africa. In patients with occult hepatitis B, antibody against Hepatitis B core antigen is often detected. The clinical implications of occult hepatitis B infection for patient prognosis thus remain obscure [49]. HBsAg remains the most frequently used test for prevalence in most epidemiological surveys and allows comparisons between countries and over different time periods.

Relatively few samples were included from patients under one year of age, due to insufficient residual serum volume from most infant samples. Infant samples can give information
regarding suspected vertical transmission, although horizontal transmission may also occur in the first year of life. Infant sampling may also be confounded by maternal antibody levels. Babies born to HBsAg-positive mothers who do not become infected may be positive for anti-HBc for up to 24 months after birth from passively acquired maternal antibody [49].

We are unable to comment on rural versus urban origin of individuals included due to limited information. Prior to introduction of universal hepatitis B vaccination in South Africa, rates in urban areas were lower than in rural areas. Our samples may be biased to children originating from urban areas, who would be more likely to seek health care during febrile rash illness. Rural and urban districts actively participate in febrile rash surveillance, however, and are required to meet similar targets for surveillance adequacy. The private sector may be under-represented as surveillance officers are employed by national and provincial departments of health rather than private organizations. Surveillance officers are, however, tasked with active surveillance in both public and private institutions. The study was not powered to analyse whether differences existed in rates of HBsAg carriage per province. Increasing the sample size to include representative numbers of samples from each province could be performed in future to give geographic estimates of disease prevalence.

Previous studies on hepatitis B in the post-vaccination era have largely been conducted in localized health-care facilities or from tertiary referral centres, with the majority of patients drawn from one or two provinces. A strength of our study is the national distribution of samples included. Despite the non-measles febrile rash illness of our participants, they are unlikely to be drawn from particularly high or low risk groups for vaccination completion as viral rash illness is not vaccine preventable and patients with rash are therefore a “biologically arbitrary” selection. Since febrile rash surveillance is performed in a similar fashion by most WHO member states, this study design represents a convenience sample that could be replicated in other countries in order to inform regional prevalence and immunity figures. Representivity of rash surveillance samples may be skewed in countries with routine rubella immunisation, where febrile rash samples may be biased towards unvaccinated children. Rubella immunisation is not currently part of the South African routine immunisation schedule.

In conclusion, we report HBsAg prevalence of 0.4% in South African children from a period in which the Expanded Programme on Immunisation schedule included three primary doses but no booster or birth dose. While studies with active community-based random sampling are the gold standard for seroprevalence studies, residual samples from febrile rash surveillance are a low-cost proxy that can be repeated annually and can offer insights regarding disease trends over time. Febrile rash surveillance samples could also be used to study seroprevalence of other diseases.

| Age groups (n) | 0-11months | 1-5years | 6-10years | 11-14years | Total |
|---------------|------------|----------|-----------|------------|-------|
| n %           | n %        | n %      | n %       | n %        |       |
| Infected (HBsAg+) | 0 0.0 | 1 0.5 | 0 0.0 | 1 2.1 | 2 0.4 |
| Vaccine Immunity (anti-HBs+ and anti-HBc-) | 9 81.8 | 174 80.2 | 105 60.3 | 31 31.3 | 303 67.3 |
| Natural exposure (anti-HBc+) | 1 9.1 | 5 2.3 | 6 3.4 | 1 2.1 | 13 2.9 |
| No evidence of natural exposure or vaccine immunity (HBsAg-, anti-HBs- and anti-HBc-) | 1 9.1 | 37 17.1 | 63 36.2 | 31 64.6 | 132 29.3 |
| Total | 11 100.0 | 217 100.0 | 174 100.0 | 48 100.0 | 450 100.0 |

HBsAg hepatitis B surface antigen; anti-HBs Hepatitis B surface antibody; anti-HBc Hepatitis B core antibody; + positive - negative; n number. Percentages shown in darker shade with totals reflecting column totals.

https://doi.org/10.1371/journal.pone.0217415.t001
Supporting information

S1 Supporting Dataset. (XLSX)

Acknowledgments

The authors would like to acknowledge the Hepatitis B Virus Diversity Unit at the University of the Witwatersrand for help and advice with sequencing data analyses.

Author Contributions

Conceptualization: Cheryl Cohen, Melinda Shelley Suchard.
Data curation: Nishi Prabdial-Sing, Morubula Jack Manamela, Nkengafac Villyen Motaze.
Formal analysis: Nishi Prabdial-Sing, Nkengafac Villyen Motaze, Melinda Shelley Suchard.
Funding acquisition: Melinda Shelley Suchard.
Investigation: Nishi Prabdial-Sing, Lillian Makhathini, Sheilagh Brigitte Smit, Nkengafac Villyen Motaze.
Methodology: Lillian Makhathini, Sheilagh Brigitte Smit, Nkengafac Villyen Motaze, Cheryl Cohen, Melinda Shelley Suchard.
Project administration: Sheilagh Brigitte Smit, Morubula Jack Manamela.
Supervision: Melinda Shelley Suchard.
Writing – original draft: Nishi Prabdial-Sing.
Writing – review & editing: Nkengafac Villyen Motaze, Cheryl Cohen, Melinda Shelley Suchard.

References

1. Hepatitis B Vaccines—WHO position paper. World Health Organization, Weekly Epidemiological Record. 2017.
2. Kew MC. Hepatitis B virus infection: the burden of disease in South Africa. Southern African Journal of Epidemiology and Infection. 2008; 23(1):4–8. https://doi.org/10.1015/s01587822008.11441293
3. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine. 2012; 30 Suppl 3:C45–51. https://doi.org/10.1016/j.vaccine.2012.02.021 PMID: 22939021.
4. Dusheiko GM, Conradie JD, Brink BA, Marimuthu T, Sher R. Differences in the regional prevalence of chronic hepatitis B in southern Africa—implications for vaccination. S Afr Med J. 1989; 75(10):473–8. PMID: 2524893.
5. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut. 1996; 38 Suppl 2:S31–6. https://doi.org/10.1136/gut.38.suppl_2.s31 PMID: 8786050; PubMed Central PMCID: PMC1398040.
6. Abdool Karim SS, Coovadia HM, Windsor IM, Thejpal R, van den Ende J, Fouche A. The prevalence and transmission of hepatitis B virus infection in urban, rural and institutionalized black children of Natal/ KwaZulu, South Africa. Int J Epidemiol. 1988; 17(1):168–73. https://doi.org/10.1093/ije/17.1.168 PMID: 2898404.
7. Dibisceglie AM, Kew MC, Dusheiko GM, Berger EL, Song E, Paterson AC, et al. Prevalence of hepatitis B virus infection among black children in Soweto. Br Med J (Clin Res Ed). 1986; 292(6533):1440–2. https://doi.org/10.1136/bmj.292.6533.1440 PMID: 3067462; PubMed Central PMCID: PMCPMC1340439.
8. Vardas E, Mathai M, Bluauw D, McAneney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol. 1999; 58(2):111–5. PMID: 10335856.
9. Spengane Z, Korsman S, Mkentane K, Davids LM, Zemanay W, Africa M, et al. Blood and virus detection on barber clippers. S Afr Med J. 2018; 108(4):278–82. https://doi.org/10.7196/SAMJ.2017.v108i4.12830 PMID: 29629677.

10. Abdool Karim SS, Thejpal R, Coovadia HM. Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa. Int J Epidemiol. 1991; 20(2):495–503. https://doi.org/10.1093/ije/20.2.495 PMID: 1917255.

11. Kew MC, Reis P, Macnab GM, Setefi HC, Bersohn I. The witch-doctor and tribal scarification of the skin and the hepatitis B antigen. S Afr Med J. 1973; 47(50):2349–20. PMID: 4795161.

12. Butler LM, Neilands TB, Mosam A, Mzolo S, Martin JV. A population-based study of how children are exposed to saliva in KwaZulu-Natal Province, South Africa: implications for the spread of saliva-borne pathogens to children. Trop Med Int Health. 2010; 15(4):442–53. https://doi.org/10.1111/j.1365-3156.2010.02474.x PMID: 20149165; PubMed Central PMCID: PMCPMC4104610.

13. Dlamini NR, Maja P. The Expanded Programme on Immunisation in South Africa: A story yet to be told. S Afr Med J. 2016; 106(7):675–7. https://doi.org/10.7196/SAMJ.2016.v106i7.10956 PMID: 27384357.

14. South Africa: WHO and UNICEF estimates of immunization coverage: 2017 revision. World Health Organisation. 2017;July 7, 2018:1–17. Epub http://www.who.int/immunization/monitoring_surveillance/data/zaf.pdf.

15. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212–9. https://doi.org/10.1016/j.vaccine.2011.12.116 PMID: 22273662.

16. Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine. 2015; 33(36):4618–22. https://doi.org/10.1016/j.vaccine.2015.06.076 PMID: 26163924.

17. Hoffmann CJ, Mashabela F, Cohn S, Hoffmann JD, Lala S, Martinson NA, et al. Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa. J Int AIDS Soc. 2014; 17:18871. https://doi.org/10.7448/IAS.17.1.18871 PMID: 24855985; PubMed Central PMCID: PMCPMC4032505.

18. South African National HIV Prevalence, Incidence and Behaviour Survey Report. Human Sciences Research Council. 2012.

19. Venter WDF, Majam M, Akpomiemie G, Arulappan N, Moorhouse M, Mashabane N, et al. Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial. BMC Public Health. 2017; 17(Suppl 3):445. https://doi.org/10.1186/s12889-017-3953-1 PMID: 28832288.

20. Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, Firnhaber C. HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther. 2010; 15(3 Pt B):499–503. https://doi.org/10.3851/IMP1494 PMID: 20516571; PubMed Central PMCID: PMCPMC3001165.

21. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008; 98(7):541–4. PMID: 18785395; PubMed Central PMCID: PMCPMC3008405.

22. Hoffmann CJ, Dayal D, Chiyip M, McIntyre JA, Gray GE, Conway S, et al. Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS. 2012; 23(10):e10–3. https://doi.org/10.1258/ijisa.2009.009340 PMID: 23104758; PubMed Central PMCID: PMCPMC3724418.

23. Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. S Afr Med J. 2000; 77(1):13–5. PMID: 10944831.

24. Boyles TH, Cohen K. The prevalence of hepatitis B infection in a rural South African HIV clinic. S Afr Med J. 2011; 101(7):470–1. PMID: 21920100.

25. Hamers RL, Zaaier HL, Wallis CL, Siwale M, Ive P, Botes ME, et al. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013; 64(2):174–82. https://doi.org/10.1097/QAI.0b013e3182a60f7d PMID: 23892239.

26. Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt—that is the question. PLoS One. 2012; 7(10):e45750. https://doi.org/10.1371/journal.pone.0045750 PMID: 23049685; PubMed Central PMCID: PMCPMC3462206.

27. Barth H. Insights into the role of interferon lambda in hepatitis C virus infection. J Hepatol. 2011; 54(5):844–7. https://doi.org/10.1016/j.jhep.2010.10.008 PMID: 21145814.
28. Mayaphi SH, Roussou TM, Masemola DP, Olorunju SA, Mphahlele MJ, Martin DJ. HBV/HIV coinfection: the dynamics of HBV in South African patients with AIDS. S Afr Med J. 2012; 102(3 Pt 1):157–62. PMID: 22380911.

29. Mphahlele MJ, Lukwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006; 35(1):14–20. https://doi.org/10.1016/j.jcv.2005.04.003 PMID: 15916918.

30. Lukwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009; 81(3):406–12. https://doi.org/10.1002/jmv.21418 PMID: 19152393.

31. Ayuk J, Mphahlele J, Bessong P. Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART. S Afr Med J. 2013; 103(5):330–3. PMID: 23971125.

32. Thumbirani NV, Moodley D, Parboosing R, Moodley P. Hepatitis B and HIV coinfection in pregnant women: indication for routine antenatal hepatitis B virus screening in a high HIV prevalence setting. S Afr Med J. 2014; 104(4):307–9. PMID: 25118561.

33. Diale Q, Pattinson R, Chokoe R, Masenyelets L, Mayaphi S. Antenatal screening for hepatitis B virus in HIV-infected and uninfected pregnant women in the Tshwane district of South Africa. S Afr Med J. 2015; 106(1):97–100. https://doi.org/10.7196/SAMJ.2016.v106i1.9932 PMID: 26792316.

34. Burnett RJ, Ngobeni JM, Francois G, Hoosen AA, Leroux-Roels G, Meheus A, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS. 2007; 18(3):152–6. https://doi.org/10.1258/095566306780132523 PMID: 17362544.

35. Andersson MI, Maponga TG, Ijaz S, Barnes J, Theron GB, Meredith SA, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine. 2013; 31(47):5579–84. https://doi.org/10.1016/j.vaccine.2013.08.028 PMID: 23973500; PubMed Central PMCID: PMCPMC3898695.

36. Jooste P, van Zyl A, Adland E, Daniels S, Hattingh L, Brits A, et al. Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa. J Clin Virol. 2016; 85:71–4. https://doi.org/10.1016/j.jcv.2016.07.017 PMID: 27536494; PubMed Central PMCID: PMCPMC5142290.

37. Simani OE, Leroux-Roels G, Francois G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine. 2009; 27(1):146–51. https://doi.org/10.1016/j.vaccine.2008.10.004 PMID: 18940220.

38. Younis M, Mudawi H, Hussein W, Mukhtar M, Nemer R, Glebe D, et al. Genotyping and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan. Int J Infect Dis. 2014; 29:125–32. https://doi.org/10.1016/j.ijid.2014.04.003 PMID: 25449246.

39. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA6: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011; 28(10):2731–9. https://doi.org/10.1093/molbev/msr121 PMID: 21546353; PubMed Central PMCID: PMCPMC3898695.

40. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(1):1–31. https://doi.org/10.15585/mmwr.r6701a1 PMID: 29939980; PubMed Central PMCID: PMCPMC5837403 they have no financial or competing interests with the manufacturers of commercial products or suppliers of commercial services related to hepatitis B (HepB) vaccines. Content will not include any discussion of the unlabeled use of a product or a product under investigational use, with the following exceptions: use of Pediarix vaccine for infants born to hepatitis B surface antigen (HBsAg)-positive mothers or mothers with an unknown HBsAg status to complete the vaccine series after receipt of a birth dose of single-antigen HepB vaccine and hepatitis B immune globulin (HBIG); alternate 3-dose vaccine administration schedules heeding to minimum intervals of 4 weeks between the first and second dose, 8 weeks between the second and third dose, and 16 weeks between the first and third dose; modified dosing regimens (e.g., doubling of standard dose and administration of additional doses) in certain circumstances (e.g., for persons with immunocompromising conditions); and antiviral therapy during pregnancy for the prevention of perinatal hepatitis B virus (HBV) transmission.

41. Zanetti AR, Mariano A, Romano L, D’Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366 (9494):1379–84. https://doi.org/10.1016/S0140-6736(05)67568-X PMID: 16226616.

42. Tsebe KV, Burnett RJ, Hungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine. 2001; 19(28–29):3919–26. PMID: 11427266.
43. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011; 53 (1):68–75. https://doi.org/10.1093/cid/cir270 PMID: 21653306.

44. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004; 40 (6):1415–20. https://doi.org/10.1002/hep.20490 PMID: 15565627.

45. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013; 8(3):e58029. https://doi.org/10.1371/journal.pone.0058029 PMID: 23533578; PubMed Central PMCID: PMCPMC3606345.

46. Bagheri-Jamebozorgi M, Keshavarz J, Nemati M, Mohammadi-Hossainabad S, Rezayati MT, Nejad-Ghaderi M, et al. The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Hum Vaccin Immunother. 2014; 10 (12):3731–6. https://doi.org/10.4161/hv.34393 PMID: 25483689; PubMed Central PMCID: PMCPMC4514033.

47. Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele MJ. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J Med Virol. 2014; 86(6):918–24. https://doi.org/10.1002/jmv.23910 PMID: 24615635.

48. Mdialose N, Parboosing R, Moodley P. The prevalence of hepatitis B virus infection in HIV-positive and HIV-negative infants: KwaZulu-Natal, South Africa. Afr J Lab Med. 2016; 5(1):283. https://doi.org/10.4102/aajlm.v5i1.283 PMID: 28879104; PubMed Central PMCID: PMCPMC5436393 may have inappropriately influenced them in writing this article.

49. Sadeghi A, Yahyapour Y, Poortahmasebi V, Shahmoradi S, Roggeendorf M, Karimzadeh H, et al. Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection. J Viral Hepat. 2016; 23(4):282–5. https://doi.org/10.1111/jvh.12490 PMID: 26598112.